红细胞生成素及其受体与肿瘤组织乏氧的关系及对治疗的影响

郭阳

downloadPDF
文章导航 > 国际放射医学核医学杂志  > 2007,  31 > 5: (306-308)  
引用本文:
shu
Citation:
shu

红细胞生成素及其受体与肿瘤组织乏氧的关系及对治疗的影响

  • 300060 天津, 天津市环湖医院放射治疗科

  • 中图分类号: Q513.+2

Erythropoietin and erythropoietin receptor: relationship to tumor hypoxia and treatment

  • Department of Radiotheropy, Huanhu Hospital, Tianjin 300060, China

  • CLC number: Q513.+2

  • 摘要: 红细胞生成素及其受体的表达与组织乏氧关系密切.在各种实体肿瘤组织内,有大量的红细胞生成素及其受体的表达,其表达与肿瘤细胞对放射治疗和化学药物治疗抗性有关,并增加肿瘤的局部侵袭能力和转移能力,临床上,实体肿瘤患者中约有一半在肿瘤的发展和治疗过程中会出现各种程度的贫血,在贫血的肿瘤患者中使用红细胞生成素的问题还有待进一步研究.
    Abstract: The expression of erythropoietin and its receptor is very close related with the hypoxia status in tumor tissues. There are plenty of erythropoietin and erythropoietin receptor in the solid tumors. They are correlative with the resistance to the radiotherapy and chemotherapy. They also promote the invasive and migration. In clinical, there are more than an half of patients with tumor suffering from various extent of anaemia during the process of developing and treating the tumors, It is need to further investigate the use of erythropoietin in tumor patients.
  • [1] Mohyeldin A, Lu H, Dalgar d C, et al. Erythropoietin signaling promotes vasiveness of human head and neck squamous cell carcinoma. Neoplasia, 2005, 7(5):537-543.
    [2] Arcasoy MO, Amin K, Chou SC, et al. Erythropoietin and erythropoietin receptor expression in head and neck cancer:relationship to tumor hypoxia. Clin Cancer Res, 2005, 11(1):20-27.
    [3] Arcasoy MO, Amin K, Volhner RT, et al. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol, 2005, 18(3):421-430.
    [4] Arcasoy MO, Amin K, Karayal AF, et al:Functional significance of erythropoietin reeeptor expression in breast cancer. Lab Invest, 2002, 82(7):911-918.
    [5] Acs G. Zhang PJ, Rebbeck TR, et al. hnmunohistochemieal expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer, 2002, 95(5):969-981.
    [6] Acs G, Xu X, Chu C, et al. Prognostic significanee of erythropoietin expression in human endometrial carcinoma. Cancer, 2004, 100(11):2376-2386.
    [7] Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squaroous cell carcinoroa of the uterine cervix and its potential role in cervical carcinogenesis and tunror progression. Am J Pathol, 2003, 162(6):1789-1806.
    [8] Batra S, Perehnan N, Luck LR, et al. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest, 2003, 83(10):1477-1487.
    [9] Dagnon K, Pacary E, Commo F, et al. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res, 2005, 11(3):993-999.
    [10] Kumar SM Acs G, Fang D, et al. Functional erythropoietin autocrine loop in melanoma. Am J Pathol, 2005, 166(3):823-830.
    [11] Winter SC, Shah KA, Campo L, et al. Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma. Clin Cancer Res, 2005, 11(21):7614-7620.
    [12] Hale SA, Wong C, Lounsbury KM. Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells. Gynecol Oncol, 2006, 100(1):14-19
    [13] Lester RD, Jo M, Campana WM, et al. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem, 2005, 280(47):39273-39277.
    [14] Hoogsteen IJ, Peeters WJ, Marres HA, et al. Erythropoietin receptor is not a surrogate marker for tumor hypoxia and does not correlate with survival in head and neck squamous cell carcinomas. Radiother Oncol, 2005, 76(2):213-218.
    [15] Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of eportin alfa on hematologic parameter and quality of life in patients receiving nonplatinum chemotherapy:results of a randomized,double-blind, placebo-controlled clinical trials. J Clin Oncol, 2001, 19:1204-1214
    [16] Hanke M, Laszig R, Rube C, et al. Erthropoirtin to treat head and neck cancer patient with anemia undergoing radiotherapy:randomized,double-blind, placebo-controlled trial. Lancet, 2003, 362:1255-1260.
    [17] Yasuda Y, Furida Y, Matsuo T, et al. Erthropoietin regulates tumor growth of human malignancies. Carciogenesis, 2003, 24:1021-1029.
  • [1] 鞠桂芝 , 刘及 . 在红细胞生成素处理的小鼠大网膜上移植骨髓的粒细胞生成优势. 国际放射医学核医学杂志, 1978, 2(3): 59-61.
    [2] 安永恒 , 饶用清 , 贾廷珍 . 红细胞生成素可提高放疗期间子宫颈癌病人血红蛋白. 国际放射医学核医学杂志, 1995, 19(6): 280-281.
    [3] 黄进忠 , 肖佩新 , 杨家宽 . 用小鼠诱发微核修正红细胞生成最后阶段的时间. 国际放射医学核医学杂志, 1984, 8(4): 214-216.
    [4] 刘军叶 , 郭鹞 , 郭国祯 . 乏氧靶向性自杀基因治疗系统增强胰腺癌放疗效果的实验研究. 国际放射医学核医学杂志, 2006, 30(3): 168-172.
    [5] 顾菲 , 刘晓秋 . 肿瘤辐射增敏的分子机制. 国际放射医学核医学杂志, 2006, 30(5): 298-301.
    [6] 薛咏 , 刘生 , 张弘 , 陈少雄 , 刘幸光 , 卢献平 , 梁九根 , 蒋宁一 . 鼻咽癌乏氧程度与放疗中期肿瘤退缩关系的初步研究. 国际放射医学核医学杂志, 2007, 31(4): 232-234.
    [7] 林伟 , 邬恒夫 , 武兆忠 , 邓力平 , 刘影 , 吴长伟 , 丁志辉 . 99mTc-HL91显像在缺血陛脑血管病中脑乏氧组织的应用研究. 国际放射医学核医学杂志, 2008, 32(3): 165-166,174.
    [8] 司宏伟 , 徐慧琴 , 岳峤 , 耿建华 , 陈盛祖 . 肿瘤组织乏氧与葡萄糖代谢. 国际放射医学核医学杂志, 2009, 33(4): 200-203. doi: 10.3760/cma.j.issn.1673-4114.2009.04.003
    [9] 孙连生 , 张卿西 . 照前注射阿糖胞苷不能预防辐射对血小板及红细胞生成的延迟效应. 国际放射医学核医学杂志, 1995, 19(4): 191-192.
    [10] 苏新辉 , 吴华 . 99mTc-HL91乏氧显像探测肿瘤乏氧状态的研究进展. 国际放射医学核医学杂志, 2006, 30(4): 220-222.
    [11] 杜雪梅 , 张延军 . 核素乏氧显像在肿瘤放射治疗中的应用. 国际放射医学核医学杂志, 2008, 32(2): 96-98.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1397
  • HTML全文浏览量:  72
  • PDF下载量:  2
出版历程
  • 收稿日期:  2007-03-19

红细胞生成素及其受体与肿瘤组织乏氧的关系及对治疗的影响

  • 300060 天津, 天津市环湖医院放射治疗科
  • 收稿日期: 2007-03-19

摘要: 红细胞生成素及其受体的表达与组织乏氧关系密切.在各种实体肿瘤组织内,有大量的红细胞生成素及其受体的表达,其表达与肿瘤细胞对放射治疗和化学药物治疗抗性有关,并增加肿瘤的局部侵袭能力和转移能力,临床上,实体肿瘤患者中约有一半在肿瘤的发展和治疗过程中会出现各种程度的贫血,在贫血的肿瘤患者中使用红细胞生成素的问题还有待进一步研究.

English Abstract

    全文HTML

参考文献 (17)

目录

    /

    返回文章
    返回

    版权所有©中华医学会   备案号：津ICP备15006720号-3

    地址：天津市南开区白堤路238号电话：86-22-58089989
    86-22-85682389    传真：022-87890607

    本系统由 北京仁和汇智信息技术有限公司 开发 技术支持： info@rhhz.net